Moleac

Moleac launches CognivAiD™, a novel targeted product for vascular dementia

Retrieved on: 
Monday, January 16, 2023
Saffron, Acetylcholinesterase, Caregiver, Vascular dementia, Safety, Neurology, Medical Affairs Bureau, Memantine, Vad, Patient, Research, Dementia, NMDA, Incidence, Pharmaceutical industry, Moleac

CognivAiD provides a long-awaited option to fulfil the unmet needs of patients with vascular dementia.

Key Points: 
  • CognivAiD provides a long-awaited option to fulfil the unmet needs of patients with vascular dementia.
  • SINGAPORE, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Moleac announced on 29th October 2022 the launch of CognivAiD™, the first-in-market specific product for Vascular Dementia (VaD).
  • David Picard, CEO of Moleac, commented on the launch: “Moleac focuses on neurology to help patients reconnect with their lives.
  • Vascular dementia, the second most common subtype of dementia after Alzheimer’s disease, accounts for 15-30% of all dementia cases 2 .

Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery

Retrieved on: 
Monday, May 31, 2021
Health sciences, Clinical research, Health, Food and Drug Administration, Drug Safety, Investigational New Drug, Pharmaceutical industry, Moleac, Criticism of the Food and Drug Administration, Genta

SINGAPORE, May 31, 2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based in Singapore, announced the approval by the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for MLC1501 in traumatic brain injury (TBI).

Key Points: 
  • SINGAPORE, May 31, 2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based in Singapore, announced the approval by the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for MLC1501 in traumatic brain injury (TBI).
  • The approval of this IND comes 3 years after the opening of the first IND by the U.S. FDA for MLC1501 in Post-Stroke Recovery, allowing Moleac to conduct a phase 1 study (safety study) in healthy volunteers which has been successfully completed.
  • "This approval represents another milestone for Moleac, supporting our ambition to provide best in class therapeutic options to patients in need.
  • In 2018, the U.S. FDA has approved an IND for MLC1501 in post-stroke recovery, the phase 1 was completed in 2020.

Moleac Pte Ltd wins SBR National Business Award for Pharmaceuticals

Retrieved on: 
Thursday, May 6, 2021
Moleac, Medication, Neurological disorder, Neurotrauma, Natural sciences, Life sciences

b'SINGAPORE, May 6,2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based in Singapore, wins SBR National Business Award for Pharmaceuticals.\nMoleac is dedicated in finding, developing and commercialising new medicines for the unmet medical needs of patients suffering from central nervous system diseases and injuries.

Key Points: 
  • b'SINGAPORE, May 6,2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based in Singapore, wins SBR National Business Award for Pharmaceuticals.\nMoleac is dedicated in finding, developing and commercialising new medicines for the unmet medical needs of patients suffering from central nervous system diseases and injuries.
  • Stroke not only endangers the lives of stroke survivors, but also burdens families with significant caretaking and financial expenses.
  • This would mean an improvement of day-to-day functioning of patients who have experienced a neurological condition.
  • A second IND was recently approved for MLC1501 in TBI.\n'

Moleac Pte Ltd wins SBR National Business Award for Pharmaceuticals

Retrieved on: 
Thursday, May 6, 2021
Moleac, Medication, Neurological disorder, Neurotrauma, Natural sciences, Life sciences

b'SINGAPORE, May 6,2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based in Singapore, wins SBR National Business Award for Pharmaceuticals.\nMoleac is dedicated in finding, developing and commercialising new medicines for the unmet medical needs of patients suffering from central nervous system diseases and injuries.

Key Points: 
  • b'SINGAPORE, May 6,2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based in Singapore, wins SBR National Business Award for Pharmaceuticals.\nMoleac is dedicated in finding, developing and commercialising new medicines for the unmet medical needs of patients suffering from central nervous system diseases and injuries.
  • Stroke not only endangers the lives of stroke survivors, but also burdens families with significant caretaking and financial expenses.
  • This would mean an improvement of day-to-day functioning of patients who have experienced a neurological condition.
  • A second IND was recently approved for MLC1501 in TBI.\n'